Transmembrane protein 158 promoting osteosarcoma progression by regulating Notch signaling pathway

doi:10.16098/j.issn.0529-1356.2026.03.006

PDF(3631 KB)

Acta Anatomica Sinica ›› 2026, Vol. 57 ›› Issue (3) : 313-322. DOI: 10.16098/j.issn.0529-1356.2026.03.006

Cancer Biology

Transmembrane protein 158 promoting osteosarcoma progression by regulating Notch signaling pathway

WANG Zhen¹, MA Shi-jie¹, WANG Zi-hao¹, YAN Qiu-peng², ZHOU Feng-hua², WANG Mo-lin¹, ZHANG Ling-yun²^*, LIU Huan-cai^1*

Author information +

History +

Abstract

Objective To investigate the mechanism by which transmembrane protein 158 (TMEM158) regulates osteosarcoma progression and to identify potential targets for clinical intervention. Methods Bioinformatics analysis of the Gene Expression Omnibus(GEO) datasets indicated that high expression of TMEM158 was associated with poor prognosis in patients with osteosarcoma. RNA sequencing analysis revealed that the downregulated genes in the TMEM158 knockdown group were enriched in the Notch signaling pathway.Western blotting,Real-time PCR,CCK-8 assay,wound healing assay, and transwell assay were performed to evaluate the effects of TMEM158 knockdown and treatment with Jagged-1(188-204, TFA, an agonist of Notch receptor)on the proliferation, migration, and invasion of 143B osteosarcoma cells. Results Bioinformatics analysis and experimental validation revealed elevated expression of TMEM158 in both osteosarcoma tissue and 143B cells. Cellular experiments demonstrated that knockdown of TMEM158 in 143B cells significantly inhibited cell proliferation, invasion, and migration. Treatment with Jagged-1 effectively reversed the inhibitory effects of TMEM158 knockdown on 143B cell phenotypes. Conclusion TMEM158 may promote the progression of osteosarcoma by regulating the Notch signaling pathway, and could serve as a potential therapeutic target for osteosarcoma.

Key words

/ "> Osteosarcoma│Transmembrane protein 158│Notch signaling pathway│RNA sequencing│143B cell

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Zhen, MA Shi-jie, WANG Zi-hao, YAN Qiu-peng, ZHOU Feng-hua, WANG Mo-lin, ZHANG Ling-yun, LIU Huan-cai. Transmembrane protein 158 promoting osteosarcoma progression by regulating Notch signaling pathway[J]. Acta Anatomica Sinica. 2026, 57(3): 313-322 https://doi.org/10.16098/j.issn.0529-1356.2026.03.006

References

［1］ Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma［J］. Nat Rev Dis Primers, 2022, 8(1):77.

［2］ Park HJ, Hong KT, Choi JY, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for osteosarcoma with initial pulmonary metastases［J］. Pediatr Blood Cancer, 2025, 72(10): e31914.

［3］ Reinecke JB, Jimenez Garcia L, Gross AC, et al. Aberrant activation of wound-healing programs within the metastatic niche facilitates lung colonization by osteosarcoma cells［J］. Clin Cancer Res, 2025, 31(2):414-429.

［4］ Rubio-San-Simn A, Wilson W, Sironi G, et al. Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review［J］. Br J Cancer, 2025, 133(7):1020-1028.

［5］ Sholevar CJ, Liu NM, Mukarrama T, et al. Myeloid cells in the immunosuppressive microenvironment as immunotargets in osteosarcoma［J］. Immunotargets Ther, 2025, 14:247-258.

［6］ Shi J, Zheng D, Yao B, et al. Research progress on TMEM proteins in cancer progression and chemoresistance (review) ［J］. Int J Mol Med, 2025, 56(6): 219.

［7］ Zhu X, Liu T, Yin X. TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer［J］. Pharmacogenomics J, 2024, 24(6):34.

［8］ Jeon M, Yoo S, Park S, et al. Over-expression of transmembrane protein 158 predicts aggressive tumor behavior and poor prognosis in lung cancer［J］. Anticancer Res, 2024, 44(11):4885-4893.

［9］ Tong J, Li H, Hu Y, et al. TMEM158 regulates the canonical and non-canonical pathways of TGF-β to mediate EMT in triple-negative breast cancer［J］. J Cancer, 2022, 13(8):2694-2704.

［10］ Li J, Wang X, Chen L, et al. TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas［J］. Cancer Gene Ther, 2022, 29(8-9):1117-1129.

［11］ Fu Y, Yao N, Ding D, et al. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway［J］. J Cell Physiol, 2020, 235(3):2761-2775.

［12］ Tang D, Chen M, Huang X, et al. SRplot, a free online platform for data visualization and graphing［J］. PLoS One, 2023, 18(11):e0294236.

［13］ Liu H, Chen Y, Zhou F, et al. Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells［J］. Int J Clin Exp Pathol, 2014, 7(8):4795-4805.

［14］ Zhou G, Soufan O, Ewald J, et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis［J］. Nucleic Acids Res, 2019, 47(W1):W234-W241.

［15］ Wang ChCh, Zhang X, Gao XSh, et al. Role of SLIt-ROBO Rho GTPase-activating protein 2 in motor neuron degeneration in amyotrophic lateral sclerosis［J］. Acta Anatomica Sinica, 2025, 56(4):413-420.(in Chinese)

［16］ Liao Y, Chen J, Yao H, et al. Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma［J］. J Transl Med, 2025, 23(1):103.

［17］ Schmit K, Michiels C. TMEM proteins in cancer: a review［J］. Front Pharmacol, 2018, 9:1345.

［18］ Liu L, Zhang J, Li S, et al. Silencing of TMEM158 inhibits tumorigenesis and multidrug resistance in colorectal cancer［J］. Nutr Cancer, 2020, 72(4): 662-671.

［19］ Huang J, Liu W, Zhang D, et al. TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers［J］. Front Oncol, 2022, 12:1023455.

［20］ Zhang J, Li N, Lu S, et al. The role of notch ligand jagged1 in osteosarcoma proliferation, metastasis, and recurrence［J］. J Orthop Surg Res, 2021, 16(1):226.

［21］Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics［J］. Signal Transduct Target Ther, 2022, 7(1):95.

［22］ Yao K, Zhan XY, Feng M, et al. Furin, ADAM, and γ-secretase: core regulatory targets in the notch pathway and the therapeutic potential for breast cancer［J］. Neoplasia, 2024, 57:101041.

［23］ Sen P, Ghosh SS. The intricate notch signaling dynamics in therapeutic realms of cancer［J］. ACS Pharmacol Transl Sci, 2023, 6(5):651-670.

［24］ Shi Q, Xue C, Zeng Y, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies［J］. Signal Transduct Target Ther, 2024, 9(1):128.

［25］ Zhang Z, Wu W, Shao Z. NOTCH signaling in osteosarcoma［J］. Curr Issues Mol Biol, 2023, 45(3):2266-2283.

［26］ Tang XF, Cao Y, Peng DB, et al. Overexpression of notch3 is associated with metastasis and poor prognosis in osteosarcoma patients［J］. Cancer Manag Res, 2019, 11:547-559.